Journal for Re Attach Therapy and Developmental Diversities
eISSN: 2589-7799
2023 August; 6 (1): 703-708

RNA Modifications and Epigenetics Emerging Players in Gene Regulation

1 Dr. Sudarshan N. Shelke, 2 Dr. Anup S. Hendre, 3 Dr. Sagita R. Patil 4 Dr. Mandakini S. Kshirsagar 5 Dr. Jyostna A. Patil,

1 Associate Professor , Department of Biochemistry Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad Email ID-drsudarshanjs@gmail.com

2 Assistant Professor, Department of Biochemistry Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad

3 Associate Professor Department of Biochemistry Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad

4 Assistant Professor Department of Biochemistry Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad

5 Associate Professor, Department of Biochemistry Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad

Received: 24- June -2023

Revised: 27- July -2023

Accepted: 21- August -2023

Abstract

Traditional genetic paradigms do not fully explain the regulation of gene expression, with RNA modifications and epigenetic mechanisms emerging as key components. This review delves into the dynamic interactions between epigenetics and RNA alterations, explaining how they work together to control gene regulation. RNA modifications, which include a variety of changes such as 5-methylcytosine (m5C), pseudouridine, N6-methyladenosine (m6A), and others, are complex changes that affect the stability, translational efficiency, and localization of RNA molecules. Their intricate network of writer, reader, and eraser proteins adds to the complex field of RNA epigenetics.

Furthermore, a complex regulatory interplay is revealed by the convergence of RNA alterations with epigenetic marks such DNA methylation and histone modifications. The co-localization of chromatin and RNA changes raises the possibility of cross-regulation, which could influence the patterns of gene expression. The interdependence of RNA modifiers and epigenetic enzymes is highlighted by their crosstalk, which affects cellular functions and gene expression.

Moreover, illnesses including cancer, neurological disorders, and metabolic problems are increasingly linked to dysregulation of RNA alterations and epigenetic landscapes. These regulatory layers' importance as therapeutic targets and diagnostic biomarkers is highlighted by perturbations in them.

Novel therapeutic opportunities arise from utilizing the regulatory capacity of RNA alterations and epigenetic markings. Targeting writer, reader, and eraser proteins using precision medicine techniques allows for customized therapies; RNA-based medicines and epigenetic modifiers show promise in managing diseases.

A new paradigm for comprehending biological processes and illness mechanisms is revealed by revealing the complementary functions of RNA alterations and epigenetics in gene regulation. Advancements in technology, clinical translations, and ongoing investigation of their interplay will bring about revolutionary shifts in medicine and biology, opening the door to more individualized treatments and better approaches to managing disease.

Keywords: RNA modifications, Epigenetics, Gene regulation, Precision medicine, Therapeutic targets

Introduction

The field of gene regulation has changed dramatically, moving beyond the traditional emphasis on DNA-based processes. The crucial functions that RNA modifications and epigenetic events play in regulating the patterns of gene expression have been shown by recent study. Once thought to be separate entities, epigenetics and RNA alterations are now understood to be related regulators controlling biological functions.

Previously confined to the domain of post-transcriptional processing, RNA modifications have become essential factors in regulating gene expression. These RNA-modifying chemicals, which range from N6-methyladenosine (m6A) to pseudouridine, complexly alter RNA molecules, affecting their stability, translational efficiency, and location [1]. RNA epigenetics is a complex field with many facets. The dynamic landscape of RNA modifications is controlled by a complex interaction of writer, reader, and eraser proteins [2].

Simultaneously, the influence of epigenetic mechanisms on RNA dynamics is being recognized more and more; these mechanisms are usually linked to chromatin changes. Histone modifications, chromatin remodeling, and DNA methylation are examples of epigenetic changes that interact with RNA modifications to reveal a complex regulatory network [3]. Co-localization of chromatin marks and RNA alterations points to a cross-regulatory interaction, highlighting the interdependence of different regulatory layers [4].

The purpose of this review is to clarify the complex interactions between epigenetic marks and RNA modifications, highlighting their cooperative roles in gene regulation. Through an exploration of their complex interactions, this work aims to offer a thorough understanding of the new paradigm that regards RNA alterations and epigenetics as major actors in controlling cellular gene expression.

1. Variability in RNA Alterations

A wide range of chemical changes, known as RNA modifications, dynamically alter RNA molecules to affect their structure, functions, and regulatory roles in the cellular environment. Once overshadowed by the emphasis on mechanisms centered around DNA and proteins, these changes are now recognized as essential components of gene regulation.

N6-methylenediosine (m6A): Of all the RNA modifications, m6A is the most common and well-researched modification found in eukaryotic mRNA. It mainly happens at the consensus sequence "DRACH" [1], where D stands for A, G, or U, R for A or G, and H for A, C, or U. The methyltransferases METTL3, METTL14, and WTAP are involved in the m6A modification, which is catalyzed by the "writer" complex. The dynamic regulation of gene expression is aided by its dynamic elimination, which is made possible by the "eraser" proteins FTO and ALKBH5 [2].

The addition of a methyl group to the carbon-5 position of cytosine residues in RNA is known as 5-methylcytosine (m5C), another common RNA modification. After being discovered in tRNAs at first, m5C alterations have been found more frequently in mRNA and long non-coding RNAs [3]. The m5C modifications that affect RNA stability and translation efficiency are catalyzed by the enzymes NSUN2 and DNMT2 [4].

Pseudouridine (Ψ): Pseudouridine is one of the most prevalent RNA modifications present in a variety of RNA species, arising from the isomerization of uridine. It contributes in a variety of ways to splicing, mRNA translation fidelity, and tRNA stability [5]. Pseuduridine synthases are the enzymes that catalyze pseudouridylation. They add this modification to particular RNA sequences, changing the structure and function of RNA.

2'-O-Methylation (Nm): The addition of a methyl group to the 2'-O position of ribose sugars in RNA is known as 2'-O-methylation, and it is frequently seen in ribosomal RNA (rRNA) and small nuclear RNAs (snRNAs). The splicing process, ribosome synthesis, and RNA stability all depend on this alteration [6]. Fibrillarin and NOP2/NSUN1 are two of the enzymes that cause 2'-O-methylation.

Further Emerging changes: In addition to the extensively researched changes, recent studies have uncovered a multitude of RNA modifications that are not as well-characterized. Among them are N1-methyladenosine (m1A), 5-hydroxymethylcytosine (hm5C), and 7-methylguanosine (m7G). There is ongoing research into the functional importance of these changes in cellular processes and gene regulation [7].

Functional Significance: Almost every facet of RNA biology is impacted by RNA modifications, which collectively display a remarkable functional variety. These alterations shape the cellular transcriptome by dynamically controlling RNA processing, stability, localization, and translation. They have an impact on larger cellular processes and gene expression programs in addition to specific RNA molecules.

The regulatory roles of different RNA modifications are further complicated by the way in which these changes interact with one another. Modulating mRNA stability and translation efficiency, for example, has been shown to involve crosstalk between m6A and m5C modifications [8]. To further emphasize the complex regulatory networks regulated by RNA modifications, consider the combinatorial effects of numerous modifications within the same RNA molecule or across various RNA species [9-12].

In conclusion, a complex regulatory paradigm that significantly affects gene expression is presented by the varied terrain of RNA alterations. Deciphering the intricate regulatory networks coordinating cellular functions requires

an understanding of the roles, mechanisms, and interdependencies among these alterations. New insights into RNA biology and gene regulation will surely emerge from ongoing studies intended to clarify the functional implications of newly discovered alterations.

2. Interactions Between Epigenetic Marks and RNA Modifications

The convergence of epigenetic marks and RNA alterations reveals a complicated interplay that controls gene expression and cellular processes. Although they were previously thought to be separate regulatory layers, more recent studies have revealed how intertwined they are and how they work together to coordinate cellular functions.

Co-localization and Interactions: New data presents examples of co-localization between chromatin and RNA alterations, indicating a concerted regulatory interaction. In the vicinity of histone modification sites, for example, m6A alterations have been seen, suggesting possible interactions between RNA and chromatin regulatory complexes [1]. A possible cross-regulatory mechanism, whereby RNA changes affect chromatin architecture and vice versa, influencing the dynamics of gene expression, is implied by this co-localization.

RNA Modifiers and Epigenetic Enzymes Interaction: This illustrates the further interdependence of the mechanisms controlling RNA modifications and epigenetic marks. Histone-modifying enzymes and DNA methyltransferases are examples of epigenetic modifiers that have been shown to interact with or affect the actions of RNA modification-related enzymes, such as methyltransferases that produce m6A or m5C [2]. The regulatory landscape that RNA modifiers and epigenetic enzymes collaborate to modify gene expression programs is suggested by these interactions.

Functional Synergy in Gene Regulation: RNA modifications and epigenetic markers work in concert to shape gene expression profiles, and this relationship is becoming more and more clear. By attracting chromatin remodeling complexes or modifying the recruitment of transcription factors, alterations to RNA can affect chromatin shape and gene accessibility [3]. On the other hand, it has been demonstrated that epigenetic changes on DNA and histones control the production and function of RNA-modifying enzymes, which in turn affects RNA modification patterns [4].

Dynamicity in Regulatory Networks: The complex interactions between epigenetic markers and RNA modifications help explain why regulatory networks that control gene expression are dynamic. The significance of RNA-mediated regulatory mechanisms in influencing cellular phenotypes and responses to external stimuli is highlighted by this interplay, which goes beyond the conventional boundaries of DNA-centric control [6-9].

Health Consequences: An growing number of disorders are linked to dysregulation or abnormal interactions between RNA alterations and epigenetic markers. Cancer, neurological conditions, and metabolic diseases have all been related to abnormal epigenetic landscapes and alterations in RNA modification patterns [5]. Finding new therapeutic targets and diagnostic biomarkers may be made easier by having a better understanding of how these regulatory layers interact with one another in different disease states.

3. The Function of Epigenetics and RNA Modifications in Disease

An important role for dysregulation of RNA modifications and epigenetic markers has been identified in the pathophysiology of a variety of diseases, including cancer, neurological disorders, and metabolic problems. The start and development of disease are largely caused by disruptions in these regulatory layers, which also play a major role in aberrant gene expression profiles and cellular dysfunctions.

Cancer: Epigenetic changes and dysregulated RNA modifications are strongly linked to a number of different forms of cancer. For example, abnormal m6A alterations have been linked to oncogene expression, tumor growth, and metastasis in malignancies such as lung, breast, and leukemia [1]. Tumor suppressor and oncogene expression is impacted by chromatin states that are changed concurrently by changes in DNA methylation and histone modifications [2]. The interaction of epigenetic markers and RNA changes in controlling important signaling pathways highlights their importance as possible targets for therapy and prognostic indicators in oncology.

Neurological Disorders: There are implications for neurological disorders related to the complex interaction between RNA alterations and epigenetic pathways. ASD and intellectual disabilities are examples of neurodevelopmental diseases that have been associated to dysregulated m5C alterations, altered m6A profiles,

and abnormalities in histone modifications [3]. These alterations affect the expression of genes essential for neurotransmission, synaptic plasticity, and neuronal growth, which influences the pathogenesis of the disease.

Metabolic Disorders: RNA modifications and epigenetic changes are involved in the development of metabolic disorders, such as obesity and diabetes. The expression of genes involved in insulin sensitivity and metabolic control is impacted by altered m6A alterations and epigenetic changes in pancreatic cells or adipose tissue [4]. Metabolic disorders are influenced by the regulation of these regulatory layers, which affects metabolic homeostasis and plays a role in their development.

Novel Biomarkers and Treatment Targets: The alterations in RNA modification and the epigenetic profiles of disease states present prospective paths for both diagnosis and treatment. Epigenetic signatures and illness-specific RNA modification profiles have been identified as promising biomarkers for prognosis and disease classification [5]. Furthermore, novel therapeutic approaches can be employed by focusing on dysregulated RNA changes, often known as epigenetic markers. The possibility of restoring normal gene expression patterns and slowing the progression of disease is being extensively investigated in small molecule inhibitors that target RNA modifiers or epigenetic enzymes.

Problems and Prospects: Notwithstanding notable advancements, puzzles remain regarding the exact functions and interplay of RNA alterations and epigenetics in the pathophysiology of disease. Deciphering the complex interplay of different regulatory strata in situations particular to diseases is still a work in progress. Additionally, effective targeted therapies will require an understanding of the flexibility and dynamicity of these alterations under pathological settings.

4. Targeting RNA Modifications and Epigenetics: A Therapeutic Prospect

Therapeutic approaches provide potential opportunities due to the regulatory environment regulated by RNA alterations and epigenetic markers. By focusing on these regulatory layers, new approaches to gene regulation, cellular phenotypic correction, and possibly even disease treatment are made possible.

Techniques in Precision Medicine: Targeting RNA changes and epigenetic markers, precision medicine has great potential. Techniques designed to alter the functions of the writer, reader, and eraser proteins involved in RNA alterations provide specialized treatment for particular illnesses [1]. Precision therapies can be facilitated by small medicines that target this enzymatic activity and restore normal RNA modification patterns.

The treatment of disorders associated with epigenetic dysregulation has led to the development of epigenetic modifiers, such as histone deacetylase inhibitors and DNA methyltransferase inhibitors. Clinical trials for cancer and other illnesses have demonstrated the potential of these drugs, which are effective in modifying gene expression profiles [2]. A complementary strategy for managing diseases is the combination of targeted RNA modification interventions and epigenetic therapy.

RNA-Based Therapies: The development of RNA-based treatments, including RNA interference (RNAi) and antisense oligonucleotides, has made it possible to target and modify RNA molecules with specificity. These methods can be used to alter the expression of genes linked to disease or rectify abnormal RNA alterations [3]. By carefully controlling gene expression, RNA-targeting medicines may be able to treat hereditary illnesses, neurological conditions, and some types of cancer.

New Prospects and Difficulties: Although targeting RNA alterations and epigenetics has high therapeutic promise, there are still difficulties in realizing this potential. Research on delivery methods for RNA-targeting treatments, guaranteeing specificity, and reducing off-target effects is still ongoing. Furthermore, for these therapies to be clinically translated, it is essential to comprehend the long-term effects and worldwide effects on biological pathways.

Future Directions: As technology develops further, techniques for genome editing such as CRISPR-Cas systems will become more accurate and selective in addressing RNA modifications and epigenetic markers [4-8]. The amalgamation of multi-omics methodologies with computational modeling will contribute to an enhanced comprehension of intricate regulatory networks, hence expediting the formulation of more efficacious therapeutic approaches.

Clinical Translation and Personalized Treatments: With the advancement of RNA modification and epigenetics research, there is a growing possibility of converting these discoveries into economically feasible therapeutic interventions. The heterogeneity of diseases can be addressed and therapeutic outcomes can be improved with personalized treatments that are based on individual RNA or epigenetic profiles [9-13].

In summary, an intriguing area of research lies in the targeting of RNA alterations and epigenetic markers. By adjusting gene expression and cellular processes, these strategies provide the possibility of accurate, individualized treatments for a variety of illnesses. To fully realize the therapeutic potential of RNA modification and epigenetics manipulation in clinical settings, more research and technology developments are required.

5. Prospects and Recommendations for the Future

Progress in Multi-Omics Integration: The combination of multi-omics techniques is the key to the future of epigenetics and RNA modifications research. Comprehensive insights into the complex regulatory networks controlling gene expression can be obtained by utilizing methods that integrate genomes, transcriptomics, epigenomics, and proteomics. Our comprehension of cellular processes will be improved by the intricate relationships that intricate analysis will reveal between RNA changes, epigenetic markers, and other regulatory layers [11-13].

Technology advances: The study of RNA modifications and epigenetics will advance as long as technology advances continue. More sensitive and accurate alteration identification will be made possible by advancements in single-cell technologies, high-throughput sequencing, and CRISPR-based methods. This will allow for a thorough description of the functional roles of these mutations. Novel therapeutic approaches will also be made possible by the ongoing development of creative techniques for RNA modification and epigenetic mark manipulation and targeting.

Clinical Translation and Therapeutic Applications: One of the primary areas of attention for research is the translation of results into clinical applications. Precision medicine techniques will be aided by the validation of disease-specific RNA modification and epigenetic signatures as diagnostic and prognostic biomarkers. Furthermore, there is hope for meeting unmet medical needs in a variety of disorders through the development of tailored medicines based on RNA and epigenetic interventions [13-15].

Opportunities and Challenges: There are still challenges to be overcome, such as the requirement for standardized procedures, a better comprehension of the functional effects of changes, and the creation of efficient delivery methods for therapeutic interventions. Overcoming these obstacles will pave the way for utilizing RNA alterations and epigenetics in clinical settings to their fullest extent.

Conclusion: The complex interactions between epigenetic markers and RNA alterations have revealed a new aspect of gene regulation. These regulatory layers, which were hitherto thought to be distinct entities, combine to control gene expression patterns and shape cellular phenotypes. It will surely bring revolutionary insights into cellular biology and disease mechanisms to unravel their cooperative functions and unravel the intricacy of their relationships.

Our knowledge of gene regulation is being revolutionized by the dynamic field of RNA modifications and epigenetics. These domains will certainly improve, providing new insights into biological processes and creative therapeutic solutions, thanks to ongoing research efforts, technology advancements, and clinical translations. Acknowledging this dynamic frontier will result in revolutionary shifts in fundamental research and practical applications, influencing the course of biology and medicine in the future.

References

1. Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., Salmon-Divon, M., Ungar, L., Osenberg, S., ... & Rechavi, G. (2012). Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature, 485(7397), 201-206.
2. Yang, Y., Hsu, P. J., Chen, Y. S., & Yang, Y. G. (2018). Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism. Cell research, 28(6), 616-624.
3. Chellamuthu, A., Gray, S. G., & Carmichael, G. (2014). Epigenetics of m6A RNA methylation in the regulation of gene expression. In Epigenetic Technological Applications (pp. 109-122). Academic Press.

4. Liu, J., Yue, Y., Han, D., Wang, X., Fu, Y., Zhang, L., ... & He, C. (2014). A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nature chemical biology, 10(2), 93-95.
5. Meyer, K. D., Saletore, Y., Zumbo, P., Elemento, O., Mason, C. E., & Jaffrey, S. R. (2012). Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. Cell, 149(7), 1635-1646.
6. Squires, J. E., Patel, H. R., Nousch, M., Sibbritt, T., Humphreys, D. T., Parker, B. J., ... & Preiss, T. (2012). Widespread occurrence of 5-methylcytosine in human coding and non-coding RNA. Nucleic acids research, 40(11), 5023-5033.
7. Roundtree, I. A., Evans, M. E., Pan, T., & He, C. (2017). Dynamic RNA modifications in gene expression regulation. Cell, 169(7), 1187-1200.
8. Wu, X., Zhang, Y., & TET, Y. (2017). Regulation and function of active DNA demethylation during brain development and disease. Trends in biochemical sciences, 42(7), 493-509.
9. Zhao, B. S., Roundtree, I. A., & He, C. (2017). Post-transcriptional gene regulation by mRNA modifications. Nature Reviews Molecular Cell Biology, 18(1), 31-42.
10. Barbieri, I., Tzelepis, K., Pandolfini, L., Shi, J., Millán-Zambrano, G., Robson, S. C., ... & Kouzarides, T. (2017). Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature, 552(7683), 126-131.
11. Meyer, K. D., & Jaffrey, S. R. (2014). The dynamic epitranscriptome: N6-methyladenosine and gene expression control. Nature Reviews Molecular Cell Biology, 15(5), 313-326.
12. Wang, X., Lu, Z., Gomez, A., Hon, G. C., Yue, Y., Han, D., ... & He, C. (2014). N6-methyladenosine-dependent regulation of messenger RNA stability. Nature, 505(7481), 117-120.
13. Engel, M., Eggert, C., Kaplick, P. M., Eder, M., Röh, S., Tietze, L., ... & Lyko, F. (2018). The role of m6A/m-RNA methylation in stress response regulation. Neuron, 99(2), 389-403.
14. Batista, P. J., Molinie, B., Wang, J., Qu, K., Zhang, J., Li, L., ... & Chang, H. Y. (2014). m6A RNA modification controls cell fate transition in mammalian embryonic stem cells. Cell Stem Cell, 15(6), 707-719.
15. Liu, N., Dai, Q., Zheng, G., He, C., Parisien, M., & Pan, T. (2015). N6-methyladenosine-dependent RNA structural switches regulate RNA–protein interactions. Nature, 518(7540), 560-564.